Co-Diagnostics signs MTA with ReadyGo to test sample prep tech on Co-Dx PCR platform

Co-Diagnostics, Inc.

In August 2026, Co-Diagnostics entered a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate ReadyGo's sample collection/preparation tech.
Evaluation covers compatibility of ReadyGo's sample collection, lysis, stabilization, and prep technologies with Co-Dx PCR platform.
ReadyGo will supply sampling materials for feasibility studies; no obligation for further development, supply, or commercialization.
Co-Dx PCR platform and tests are not yet FDA-approved and are not currently available for sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.